Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial und TRANSCEND - Telmisartan randomized assessment study in ACE-I intolerant subjects with cardiovascular disease (30 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 1: ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial Abb. 2: MICARDIS ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial Abb. 3: ONTARGET trial programme Aktuelles Bild - Abb. 4: ONTARGET - background Abb. 5: ONTARGET - background Abb. 6: ONTARGET - from HOPE to ONTARGET Abb. 7: ONTARGET - the HOPE study Zum letzten Bild
Abbildung 4: ONTARGET - background
Telmisartan is an angiotensin II AT1 receptor blocker (ARB) with demonstrated antihypertensive activity. It is approved for hypertension, alone or in combination with other antihypertensive agents. Telmisartan has been shown to provide sustained 24-h blood pressure control, and remains effective even during the final 6 h of the once-daily dosing interval. [1, 2] Its antihypertensive effects are potentiated in combination with hydrochlorothiazide. [3] 1. Lacourcière Y, Lenis J, Orchard R, et al. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monit 1998;3:295-302. 2. Mallion JM, Siché JP, Lacourcière Y and the Telmisartan Blood Pressure Monitoring Group. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999;13:657-664. 3. McGill J, Reilly P. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001;23:833-850.
 
ONTARGET - background
Vorheriges Bild Nächstes Bild   


Abbildung 4: ONTARGET - background
Telmisartan is an angiotensin II AT1 receptor blocker (ARB) with demonstrated antihypertensive activity. It is approved for hypertension, alone or in combination with other antihypertensive agents. Telmisartan has been shown to provide sustained 24-h blood pressure control, and remains effective even during the final 6 h of the once-daily dosing interval. [1, 2] Its antihypertensive effects are potentiated in combination with hydrochlorothiazide. [3] 1. Lacourcière Y, Lenis J, Orchard R, et al. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monit 1998;3:295-302. 2. Mallion JM, Siché JP, Lacourcière Y and the Telmisartan Blood Pressure Monitoring Group. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999;13:657-664. 3. McGill J, Reilly P. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001;23:833-850.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung